Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability

Yewande Dosunmu, Richard Owusu-Apenten

Research output: Contribution to journalArticle

Abstract

Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate(MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS).Study Design: In-vitro method.Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay.Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l).Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1
LanguageEnglish
JournalJournal of Applied Life Sciences International
Volume14
Issue number2
DOIs
Publication statusPublished - 28 Oct 2017

Fingerprint

Dehydroascorbic Acid
Methotrexate
Ascorbic Acid
Cell Survival
Breast Neoplasms
Reactive Oxygen Species
lissamine rhodamine B
Bromides
Inhibitory Concentration 50
Biomedical Research

Keywords

  • Ascorbic acid
  • dehydroascorbic acid
  • methotrexate
  • breast cancer
  • MDA-MB-231 cells
  • Reactive oxygen species. Intracellular oxidative stress

Cite this

@article{7935e7345fea4c2a8174205bf184b456,
title = "Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability",
abstract = "Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate(MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS).Study Design: In-vitro method.Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay.Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50{\%} inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l).Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1",
keywords = "Ascorbic acid, dehydroascorbic acid, methotrexate, breast cancer, MDA-MB-231 cells, Reactive oxygen species. Intracellular oxidative stress",
author = "Yewande Dosunmu and Richard Owusu-Apenten",
year = "2017",
month = "10",
day = "28",
doi = "10.9734/JALSI/2017/37185",
language = "English",
volume = "14",
journal = "Journal of Applied Life Sciences International",
issn = "2394-1103",
number = "2",

}

Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability. / Dosunmu, Yewande; Owusu-Apenten, Richard.

In: Journal of Applied Life Sciences International, Vol. 14, No. 2, 28.10.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability

AU - Dosunmu, Yewande

AU - Owusu-Apenten, Richard

PY - 2017/10/28

Y1 - 2017/10/28

N2 - Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate(MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS).Study Design: In-vitro method.Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay.Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l).Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1

AB - Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate(MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS).Study Design: In-vitro method.Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay.Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l).Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1

KW - Ascorbic acid

KW - dehydroascorbic acid

KW - methotrexate

KW - breast cancer

KW - MDA-MB-231 cells

KW - Reactive oxygen species. Intracellular oxidative stress

U2 - 10.9734/JALSI/2017/37185

DO - 10.9734/JALSI/2017/37185

M3 - Article

VL - 14

JO - Journal of Applied Life Sciences International

T2 - Journal of Applied Life Sciences International

JF - Journal of Applied Life Sciences International

SN - 2394-1103

IS - 2

ER -